Recovery of neuromuscular function after atracurium and pancuronium maintenance of pancuronium block 
Accepted for publication 1st October, 1993 . There have been numerous studies both in adults and children which have documented prolonged neuromuscular blockade that extended into the postanaesthesia recovery period despite diligent intraoperative monitoring and seemingly adequate reversal, i- 4 The incidence of impaired neuromuscular function upon arrival in the recovery room has been shown to be approximately 40% following the use of pancuronium but less than 5% after vecuronium or atracurium suggesting the greater safety of these intermediate-acting muscle relaxants. 2.3
Cette &ude vise ~ dOterminer si la cumrisation initi~e par le pancuronium mais maintenue ,~ l'atracurium pr$sente une r~cu-p~ration complete plus rapide apr~s l'administration de n~os-tigmine que lorsque la curarisation est maintenue par le pancuronium seul. L'anesth~sie est r~alisde avec une association de thiopentone, de NzO/ O 2 avec enflurane et du fentanyl; le bloc neuromusculaire est induit par le pancuronium 0,1 mg" kg -1. Le monitorage consiste fi mesurer la force de contraction de l'adducteur du pouce pendant une chirurgie abdominale majeure d'une dur~e de 2 ~ 5 h. Chez 24 patients (groupe 1), de l'atracurium 0,07 rag" kg -t est rdp~td quand le premier twitch du train-de-quatre (TOF) revient ~ 25% du contrtle (TI/ TC25). Chez 28 patients (groupe 2), du pancuronium 0,015 mg" kg -Iest administr$ au moment oft la r~cup~ration atteint
Both vecuronium and atracurium have been used to prolong a neuromuscular blockade induced by a longacting muscle relaxant in situations where the shorter duration of action of the former drugs might prove to be advantageous, e.g., during a peritoneal closure. 5-9 This has resulted in reduced dose requirements and prolongation of action of the intermediate-acting drugs such that the drug first administered appeared to play a dominant role in influencing the duration of action of the subsequent neuromuscular blocker. 6-9 mps and Inglis have suggested that supplementary doses of atracurium 5-10 mg in an adult patient originally paralyzed with pancuronium provide enhanced neuromuscular blockade without the fear of inadequate reversal at the end of surgery. 5 However, the time to complete recovery after sequential administration of a long-and intermediateacting nondepolarizing muscle relaxant has not been investigated. The hypothesis of the present study was that a neuromuscular blockade induced with pancuronium but maintained by atracurium is associated with a shorter time to complete recovery after neostigmine than if the blockade is maintained by pancuronium alone. The interaction between the two drugs was subsequently examined.
Methods
With approval of the Institutional Review Board and informed consent, 42 adult patients without hepatic, renal or neuromuscular disease were studied during major colorectal or gynaecological surgery. Each patient received premedication with midazolam 1-3 mg/v before surgery, and anaesthesia was induced with thiopentone 3-5 mg. kg -~ and fentanyl 100-200 ~g. A control recording of neuromuscular transmission was obtained and pancuronium 0.1 mg. kg-J was subsequently given. Neuromuscular function was monitored using a Myograph 2000 | (Biometer International A/S, Odense, Denmark). The force of contraction of the adductor pollicis muscle was recorded after stimulation of the ulnar nerve at the wrist by four supramaximai square wave impulses of 200 ~tsec duration delivered at 2 Hz every 12 see through surface electrodes. The outstretched arm was enveloped in a cotton blanket and plastic bag in an attempt to minimize heat loss. After ablation of the twitch response, the patient's trachea was intubated and anaesthesia maintained with nitrous oxide 60% in oxygen, enflurane to a maximum end tidal concentration of 1%, and additional fentanyl as required.
Patients were randomly allocated to two groups and received either atracurium 0.07 mg-kg -I or pancuronium 0.015 mg. kg -l mg to maintain muscle relaxation whenever the first twitch (TI) of the train-of-four (TOF) recovered to 25% of control (TI/TC 25). Enflurane was discontinued at the end of surgery at which time neostigmine 0.07 mg.kg -~ and glycopyrrolate 0.015 mg. kg -~ were given to reverse the residual neuromuscular block which was indicated by TI/TC of less than 25% in all patients. Nitrous oxide was discontinued at a TOF ratio of 70% and the patient's trachea was extubated upon restoration of respiration. The patient was subsequently transferred to the post-anaesthesia care unit.
The following data were recorded: 1 The time to maximum twitch depression after the initial dose of pancuronium. 2 The clinical duration of the initial dose of pancuronium -time from injection to TdTC 25 recovery. 3 The number of maintenance doses -"redose" -of muscle relaxant. 4 The duration of action of each redose -the duration of a complete cycle from one TdTC 25 to the TI/ TC 25 immediately following. 5 The TI/TC at which the reversal drugs were given. 6 The recovery index -the time from T1/TC 25 to Tl/ TC 75. 7 The time taken to reach a TOF ratio of 70% (T4/ Ti 70) from the injection of the reversal drugs. Demographic and descriptive data from the two groups were compared using Student's t test for continuous variables and chi-square analysis for categorical variables. Further analyses of the relationships between the neuromuscular transmission data obtained from the two groups were performed using analysis of covariance and analysis of variance. Data were considered to be significant at a P value of less than 0.05.
Results
Of the 52 patients entered into the study, 24 were randomized to receive atracurium to maintain relaxationGroup 1 -and 28 to receive pancuronium -Group 2. The demographic data for the two groups and the duration of surgery are presented in Table I together with the time to maximum twitch depression and clinical duration of the initial dose of pancuronium. Patients in Group 2 were taller than those in Group 1 but there were no other significant differences between the groups.
Data from 20 patients in each group who had received one to four redoses of either atracurium or pancuronium were further analyzed to determine whether the use of atracurium was associated with a shorter time to complete recovery after administration of the reversal drugs (Table  II) . The mean number of redoses in Group 1 was 2.2 and in Group 2 was 2.4. Patients in both groups were given neostigmine and glycopyrrolate at a similar mean recovery of TdTC but the mean time to T4/TI 70, which was between I0 and 12 min, did not differ between groups. The recovery index was, however, smaller in Group 2. Whereas the mean recovery of TI/TC at which the reversal drugs were given was similar in both groups, the range of Tt/TC at which reversal was attempted varied between 0% and 25%. There was, however, no difference between groups in the inverse relationship of time to T4/TI 70 and T1/TC at reversal, which was significant in Group 1 ( Figure; Group 1, r = -0.585, P< 0.01). A sufficient number of patients received at least three redoses to permit a comparative analysis of the duration of action of successive redoses (Table III) . No difference was detected between the groups in the duration of action of the redoses when the results were analyzed by Student's t test.
Discussion
The study was designed to determine whether atracurium, given to maintain a neuromuscular blockade induced with pancuronium, is associated with a shorter time to complete recovery. The results suggest that this is not the case and that a maintenance dose of atracurium confers relaxation and recovery characteristics which are indistinguishable from those obtained from an equipotent dose of pancuronium for surgery lasting up to five hours.
The explanation for this observation may lie in the concept of "margin of safety" described by Paton and Waud and invoked by others in discussion of the sequential administration of long-and intermediate-acting muscle relaxants. 6'7'9'10 Approximately 75% of postjunctional receptors need to be occupied by muscle relaxant before diminution of twitch height can be observed. Administration of additional relaxant at 25% of recovery of T~ implies receptor occupancy of approximately 94% and consequently the characteristics of the blockade and subsequent recovery will be those of the muscle relaxant already occupying the majority of receptors. For example, when vecuronium is given after pancuronium, the recovery characteristics are those of pancuronium.6 In addition, pretreatment with pancuronium 0.007 mg. kg -~ has been shown to potentiate the action of a subsequent bolus of atracurium 0.1 mg-kg-J. i~ Our results together with those of Gerber et al. reinforce the observations of others that structurally dissimilar substances are likely to produce a potentiating response reflecting their action at preand postsynaptic sites at the neuromuscular junction, s.lt.t2
The present study is unique insomuch as we have demonstrated that, in the peculiar circumstances of sequential administration of different muscle relaxants, the characteristics of the initial blockade extend not only to the duration of action, but also to the time to complete recovery. Investigators from several centres have documented, both in adults and children, prolonged neuromuscular blockade despite the administration of reversal drugs that has extended well into the postanaesthesia recovery period. ~-4 This protracted impairment of neuromuscular function has been observed more commonly after blockade induced by long-acting muscle relaxants whereas atracurium was associated with a more complete recovery. ~-3 The hypothesis of the present study was that atracurium would confer more favourable recovery characteristics than if the blockade was continued with repeated pancuronium administration. However, there was no difference between the groups, not only in the depth and duration of relaxation, but also in the time from injection of the reversal drugs to T4/TI 70, which suggests that, in contrast to the proposal by Aps and Inglis,5 substituting an intermediate-acting muscle relaxant for a long-acting one confers no benefit.
Considerable variation exists in the literature as to the comparative potency of atracurium and pancuronium depending on whether the dose-response curves were generated from bolus or cumulative administration of the drugs, the age of the patients, and the simultaneous administration of volatile anaesthesia. We felt, however, that the ED95 obtained from single dose injections of muscle relaxant during balanced anaesthesia as described by Donlon et al. for pancuronium -0.053 nag-kg -I, and Sokoll et al. for atracurium -0.27 mg. kg -1, provided the most accurate assessment of potency. 13.14 We consequently chose an atracurium:pancuronium potency ratio of 5:1.
The study was unable to demonstrate cumulation with repeated doses of muscle relaxant in either group. Cumulation does not occur with atracurium, which has a very rapid distribution half-life, and is unlikely to occur when spontaneous recovery occurs after the distribution phase following a large initial dose of pancuronium.
15-18
The study was undertaken during surgery lasting between 2-5 hr. It is possible that with surgery of increasing duration the initial muscle relaxant will be removed progressively from the neuromuscular end plate and be replaced by the drug used to maintain muscle relaxation. One might expect in such circumstances that, as the initial drug is eliminated, the characteristics of the clinical duration and the recovery will become typical of the maintenance drug. Our data support such a conclusion with respect to Group 1. Within group analysis of the duration of action of up to three redoses of atracurium, shows a trend towards a shorter duration with successive redoses (Table III) . Kay et al. and Middleton et al. observed a similar decrease in the clinical duration of each redose when small increments of atracurium or vecuronium were given repeatedly after recovery to Ti/ TC 10 from a neuromuscular blockade induced by pancuronium or d-tubocurarine.7,9 In their similar publications, the same team of investigators reported that the intensity and duration of the neuromuscular blockade following the fast increment was always greater than that of subsequent increments, and ascribed a pharmacokinetic explanation to these observations based on the exponential decrease of the long-acting muscle relaxant at the neuromuscular junction and its replacement by the intermediate-acting drug. They further reported that the clinical duration of atracurium and vecuronium became constant after the third increment, and commented that despite this, a considerable proportion of receptors must still have been occupied by the long-acting muscle relaxant for such a small dose of the intermediate-acting drug to have produced a neuromuscular blockade in excess of 90%.
What is harder to explain is the decreasing duration of action of successive redoses of pancuronium in Group 2. It is difficult to understand why repeated doses of the same muscle relaxant given at the same index of recovery should not result in a similar duration of action. It is possible, however, that the fluid requirements and blood loss of our patients altered the distribution and elimination of pancuronium. Agoston et al. have suggested that the time to recovery after pancuronium is influenced not only by the drug-receptor dissociation rate constant, but also that it is directly related to the rate of change of the plasma concentration of the drug. 19 These workers demonstrated that when paneuronium is administered into the isolated arm, or systemically by bolus intravenous injection or continuous infusion, the recovery index increased from 10 rain to 23 min and 46 rain respectively. The recovery index in our patients in Group 2 was smaller than that in Group 1, suggesting a lower plasma concentration for a given degree of block, and supporting a pharmacokinetic explanation for a shorter duration of action of pancuronium with repeated doses.
In summary, we investigated the time to complete recovery after reversal from a neuromuscular blockade induced with pancuronium but maintained with atracurium during surgery lasting up to five hours. The time to complete recovery was no shorter than if the blockade was maintained with pancuronium alone.
